Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani

Blood (2021) 138 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2021-147618

Published: 2021

Journal Articles

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Nicola Vianelli, Giulia Benevolo, Alessandro Vannucchi, Claire N. Harrison, Michael Loschi, Haifa Kathrin Al-Ali, Massimiliano Bonifacio, Francisco Cervantes, Tomasz Wrobel, Giovanni Barosi, Jean-Jaques Kiladjian, Srdan Verstovsek, Ruben A. Mesa, Shelonitda Rose, Vishwanath Gharpure, Christopher Hernandez, Jun Zhang, Francesco Passamonti

Blood (2021) 138 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2021-147614

Published: 2021

Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-137279

Published: 2020

Journal Articles

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Amy S. Ruppert, PhD, Levi D. Pederson, MS, Michael V. Knopp, MD PhD, David Poon, BS, Jun Zhang, PhD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD MSSc, Lawrence H. Schwartz, MD, Wyndham H. Wilson, MD PhD, John P. Leonard, MD, Nancy L. Bartlett, MD, Heiko Schöder, MD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-139979

Published: 2020

Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett

Blood (2020) 135 (25): 2224–2234.

https://doi.org/10.1182/blood.2019003277

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ

Lei Zhang, Jing Li, Hui Xu, Xianyu Shao, Li Fu, Ye Hou, Caiqing Hao, Wenyan Li, Kanak Joshi, Wei Wei, Yan Xu, Feng Zhang, Shaojun Dai, Peter Breslin, Jiwang Zhang, Jun Zhang

Blood (2020) 135 (14): 1133–1145.

https://doi.org/10.1182/blood.2019001863

Published: 2020

Includes: Supplemental data

Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 668.

https://doi.org/10.1182/blood-2019-129288

Published: 2019

Journal Articles

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Lei Zhang, PhD, Huacheng Luo, PhD, Jing Li, Hong-Min Ni, Mark Sellin, Feng Zhang, Jun Zhang, Peter Breslin, PhD, Wei Wei, William Small, Jr., Wen-Xin Ding, Suming Huang, PhD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 3714.

https://doi.org/10.1182/blood-2019-131332

Published: 2019

Journal Articles

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis By Affecting Vwf-Gpibα Interaction

Qi Yingxue, Wenchun Chen, PhD, Ke Xu, Fengying Wu, Xuemei Fan, Shengxiang Ren, Junling Liu, Wei Deng, PhD, Jun Zhang, Renhao Li, PhD, Jianwen Liu, Xin Liang, PhD

Blood (2018) 132 (Supplement 1): 1133.

https://doi.org/10.1182/blood-2018-99-117613

Published: 2018

Journal Articles

B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

Li Li, Jun Zhang, Juan Chen, Zijun Y. Xu-Monette, Yi Miao, Min Xiao, Ken H. Young, Sa Wang, L. Jeffrey Medeiros, Michael Wang, Richard J. Ford, Lan V. Pham

Blood (2018) 132 (17): 1805–1817.

https://doi.org/10.1182/blood-2018-03-841015

Published: 2018

Includes: Supplemental data

Journal Articles

PD-L1 Expression and Gene Amplification in CD30+ Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics

George Rassidakis, MD PhD, Yi Miao, MD PhD, Jun Zhang, MD, Vassilis Atsaves, PhD, Lorand Kis, MD PhD, Karin E Smedby, MD PhD, Yong Li, PhD, Zijun Yidan Xu-Monette, PhD, Ken H. Young, MD PhD

Blood (2017) 130 (Supplement 1): 1475.

https://doi.org/10.1182/blood.V130.Suppl_1.1475.1475

Published: 2017

Journal Articles

Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

Franck Morschhauser, MD PhD, Ahmad Awada, MD PhD, Jean-Pascal Machiels, MD PhD, Gilles Andre Salles, MD PhD, Sylvie Rottey, MD PhD, Simon Rule, MD, David Cunningham, MD FRCP, Frederic Peyrade, MD, Christophe Fruchart, MD, Hendrik-Tobias Arkenau, MD PhD, Isabelle Genvresse, MD, Li Liu, PhD, Christoph Kneip, PhD, Carol Pena, PhD, Joachim Grevel, PhD, Jun Zhang, PhD, Galia Cisternas, PhD, Susanne Reschke, MSc, Camille Granvil, PhD

Blood (2017) 130 (Supplement 1): 1256.

https://doi.org/10.1182/blood.V130.Suppl_1.1256.1256

Published: 2017

Journal Articles

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young

Blood (2017) 129 (12): 1658–1668.

https://doi.org/10.1182/blood-2016-11-748855

Published: 2017

Journal Articles

Correlation Between Tumor Microenvironment and the Inflammatory Factors in Lymphoma-Burdened Mice

Jun Zhang, Jun Ni, Pei Xu, Qingqing Shi, Jian Gu, Wu Depei, MD

Blood (2015) 126 (23): 5133.

https://doi.org/10.1182/blood.V126.23.5133.5133

Published: 2015

Journal Articles

Blocking TNF and IL-1 Sensitizes AML Stem Cells to NF-κB Inhibitor Treatment

Volk Andrew, Jing Li, Jun Zhang, PhD, Joseph Cannova, Caiqin Hao, Chenglong Hu, Jiewen Sun, Yan Xu, Wei Wei, Peter Breslin, PhD, Jianjun Chen, PhD, Jiwang Zhang, MD PhD

Blood (2014) 124 (21): 2302.

https://doi.org/10.1182/blood.V124.21.2302.2302

Published: 2014

Journal Articles

Effectiveness of First and Second Line Nilotinib in Chronic Myeloid Leukemia (CML) Patients with Atypical e1a2 BCR-ABL Transcripts

Xiaomin Gui, Jinlan Pan, Huiying Qiu, Jiannong Cen, Yongquan Xue, Suning Chen, MD PhD, Jun He, Hongjie Shen, Li Yao, Jun Zhang, Yafang Wu, Wu Depei, MD

Blood (2014) 124 (21): 5520.

https://doi.org/10.1182/blood.V124.21.5520.5520

Published: 2014

Journal Articles

Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway

Blood (2014) 124 (21): 3752.

https://doi.org/10.1182/blood.V124.21.3752.3752

Published: 2014

Journal Articles

AML Cells Utilize TNF-Driven JNK Signaling As a Critical NF-κB-Independent Survival Signal

Andrew Volk, Jing Li, PhD, Junping Xin, PhD, Dewen You, PhD, Jun Zhang, PhD, Peter Breslin, PhD, Zejuan Li, MD, PhD, Wei Wei, Rachel Schmidt, Xinyu Li, MD, Zhou Zhang, PhD, Paul C Kuo, MD, Sucha Nand, MD, Jianke Zhang, PhD, Jianjun Chen, PhD, Jiwang Zhang, MD, PhD

Blood (2013) 122 (21): 2890.

https://doi.org/10.1182/blood.V122.21.2890.2890

Published: 2013

Journal Articles

Acute Differentiation Syndrome Is a Biological Consequence Of Treatment With Azanucleoside In Isocitrate Dehydrogenase-1 ( IDH-1 ) and SFR2 mutated Myelodysplasia Derived Acute Myelogenous Leukemia

Gustavo A. Rivero, MD, Dangayach Priti, MD, Jun Zhang, MD, Marylin Li, MD

Blood (2013) 122 (21): 4982.

https://doi.org/10.1182/blood.V122.21.4982.4982

Published: 2013

NARROW

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis By Affecting Vwf-Gpibα Interaction

B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

PD-L1 Expression and Gene Amplification in CD30+ Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics

Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Correlation Between Tumor Microenvironment and the Inflammatory Factors in Lymphoma-Burdened Mice

Blocking TNF and IL-1 Sensitizes AML Stem Cells to NF-κB Inhibitor Treatment

Effectiveness of First and Second Line Nilotinib in Chronic Myeloid Leukemia (CML) Patients with Atypical e1a2 BCR-ABL Transcripts

Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway

AML Cells Utilize TNF-Driven JNK Signaling As a Critical NF-κB-Independent Survival Signal

Acute Differentiation Syndrome Is a Biological Consequence Of Treatment With Azanucleoside In Isocitrate Dehydrogenase-1 ( IDH-1 ) and SFR2 mutated Myelodysplasia Derived Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only